Add to Basket
|+1 404 474 4654|
|+1 888 205 9894 (TF)|
Breast Cancer 1, Early Onset (BRCA1) antibody
|Synonyms||BRCA1, iris, pscp, brcai, brcc1, rnf53, brca1, LOC100224649, IRIS, PSCP, BRCAI, BRCC1, RNF53, BROVCA1, ARABIDOPSIS THALIANA BREAST CANCER SUSCEPTIBILITY1, ATBRCA1, breast cancer susceptibility1|
Alternatives Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunohistochemistry (IHC)
|4 references available|
|Price||957.00 $ Plus shipping costs $45.00|
|Availability||Will be delivered in 6 to 8 Business Days|
|Alternative name||BRCA1 / RNF53|
|Immunogen||Peptide corresponding to amino acids 1839-1863 of the c-terminus of BRCA1|
|Description||BRCA1 (breast and ovarian cancer susceptibility protein 1) is a nuclear phosphoprotein thatplays a role in maintaining genomic stability and acts as a tumor suppressor. It combineswith other tumor suppressors, DNA damage sensors, and signal transducers to form a largemulti-subunit protein complex known as BASC (for BRCA1 associated genome surveillancecomplex). BRCA1 associates with RNA polymerase II, and through the C terminal domain,also interacts with histone deacetylase complex. This protein thus plays a role intranscription, DNA repair of double-stranded breaks, and recombination. Mutations in theBRCA1 gene are responsible for approximately 40% of inherited breast cancers and morethan 80% of inherited breast and ovarian cancers. Alternative splicing plays a role inmodulating the subcellular localization and physiological function of this gene. Manyalternatively spliced transcript variants have been described for this gene but only somehave had their full length natures identified.|
|Characteristics||Synonyms: Breast cancer type 1 susceptibility protein, RING finger protein 53|
|Specificity||BRCA1 recognizes a 22 kD protein. This antibody stains 94 % of ovarian carcinomas with amutation in exon 11. However, staining was absent in 100 % of tumors with mutations otherthan exon 11. Cellular Localization: Cytoplasmic. Species: Human. Others not tested.|
|Application Notes||Immunohistochemistry on frozen and paraffin sections (ABC method: 1/15 - 1/50, Formalinfixed paraffin embedded tissue sections require high temperature antigen unmasking with10 mM citrate buffer, pH 6.0 prior to immunostaining, Incubation period of 30-60 minutesat room temperature). Use ovarian carcinoma as positive control. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.|
|Buffer||Tissue culture supernatant with 0.05 % sodium azide as preservative|
|Storage||Store the antibody undiluted at 2-8°C for one month or at -20°C for longer. Avoid repeatedfreezing and thawing. Should this product contain a precipitate we recommendmicrocentrifugation before use. Shelf life: One year from despatch.|
|Restrictions||For Research Use only|
Bur, Zimarowski, Schnitt et al.: "Estrogen receptor immunohistochemistry in carcinoma in situ of the breast." in: Cancer, Vol. 69, Issue 5, pp. 1174-81, 1992 (PubMed).
Graham, Jin, Lloyd: "Detection of estrogen receptor in paraffin-embedded sections of breast carcinoma by immunohistochemistry and in situ hybridization." in: The American journal of surgical pathology, Vol. 15, Issue 5, pp. 475-85, 1991 (PubMed).
Pertschuk, Kim, Nayer et al.: "Immunocytochemical estrogen and progestin receptor assays in breast cancer with monoclonal antibodies. Histopathologic, demographic, and biochemical correlations and relationship to endocrine response and survival." in: Cancer, Vol. 66, Issue 8, pp. 1663-70, 1990 (PubMed).
Kumar, Green, Stack et al.: "Functional domains of the human estrogen receptor." in: Cell, Vol. 51, Issue 6, pp. 941-51, 1988 (PubMed).